Skip to main content

Henry Schein Value Stock - Dividend - Research Selection

Henry schein

ISIN: US8064071025 , WKN: 897961

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

We believe we are the world’s largest provider of health care products and services primarily to office-based dental, animal health and medical practitioners.  We serve more than 1 million customers worldwide including dental practitioners and laboratories, animal health clinics and physician practices, as well as government, institutional health care clinics and other alternate care clinics.  We believe that we have a strong brand identity due to our more than 84 years of experience distributing health care products.

 

We are headquartered in Melville, New York, employ more than 21,000 people (of which more than 10,500 are based outside the United States) and have operations or affiliates in 33 countries, including the United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China, the Czech Republic, Denmark, France, Germany, Hong Kong SAR, Iceland, Ireland, Israel, Italy, Japan, Luxembourg, Malaysia, the Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Slovakia, South Africa, Spain, Sweden, Switzerland, Thailand and the United Kingdom.

 

We offer a comprehensive selection of products and services and value-added solutions for operating efficient practices and delivering high quality care.  We operate through a centralized and automated distribution network with a selection of more than 120,000 branded products and Henry Schein private brand products in stock, as well as more than 180,000 additional products available as special order items.  We also offer our customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

 

We have established over 4.5 million square feet of space in 62 strategically located distribution centers around the world to enable us to better serve our customers and increase our operating efficiency.  This infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our customers’ needs.  Our infrastructure also allows us to provide convenient ordering and rapid, accurate and complete order fulfillment.

 

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services.  These segments offer different products and services to the same customer base. 

 

The health care distribution reportable segment aggregates our global dental, animal health and medical operating segments.  This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.  Our global dental group serves office-based dental practitioners, dental laboratories, schools and other institutions.  Our global animal health group serves animal health practices and clinics.  Our global medical group serves office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. 

 

Our technology and value-added services group provides software, technology and other value-added services to health care practitioners.  Our technology group offerings include practice management software systems for dental and medical practitioners and animal health clinics.  Our value-added practice solutions include financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners.

 

Source: www.sec.gov

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET

2026-01-22
MELVILLE, N.Y., January 22, 2026--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its fourth quarter 2025 financial results before the stock market opens on Tuesday, February 24, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the B

Here's What to Expect From Henry Schein's Next Earnings Report

2026-01-20
Henry Schein is scheduled to announce its fiscal fourth-quarter earnings soon, and analysts project a high single-digit earnings growth.

Mixed Strategic Drivers Led Upslope Capital Management to Pick Henry Schein (HSIC)

2026-01-19
Upslope Capital Management, an investment management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Upslope aims to provide attractive, equity-like returns while reducing market risk and keeping low correlation with traditional equity strategies. The fourth quarter marked a strong end to an exceptional year for the firm. […]

Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement

2026-01-16
Henry Schein (HSIC) stock is in focus after the company secured exclusive U.S. distribution rights for CytoChip’s FDA-cleared CitoCBC system, the first cartridge-based CBC device with a CLIA Waiver for point-of-care testing. See our latest analysis for Henry Schein. Investors have reacted positively to the CitoCBC agreement and recent M&A commentary, with the share price up 23.98% over the past 90 days and a 1-year total shareholder return of 8.82%. This suggests improving momentum after a...

Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer

2026-01-15
IRVINE, Calif., January 15, 2026--Henry Schein, Inc. (Nasdaq: HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care

3 Reasons to Sell HSIC and 1 Stock to Buy Instead

2026-01-15
Henry Schein trades at $76.27 per share and has stayed right on track with the overall market, gaining 8% over the last six months. At the same time, the S&P 500 has returned 11.5%.

Biomerica Reports Second Quarter Fiscal 2026 Financial Results

2026-01-14
Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights: 1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein During the secon

Henry Schein, Inc. (HSIC) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

2026-01-14
2026-01-14. The following slide deck was published by Henry Schein, Inc.

JPM26: Henry Schein focuses on high-margin, high-growth business as new CEO announced

2026-01-14
Henry Schein currently has a broad portfolio with over $3bn in corporate and owned brand products and services.

4 Stocks That Accelerated Growth In Its Smaller, But Higher Margin Segments

2026-01-13
Upslope Capital's Q4 2025 letter details new positions in Booz Allen Hamilton and Crown Holdings amid shifting macro conditions. Read the full investment thesis now.